PETNET to distribute Lilly's Alzheimer's imaging agent

by Brendon Nafziger, DOTmed News Associate Editor | November 07, 2011
Siemens' subsidiary PETNET Solutions Inc. has inked a deal with Eli Lilly and Company to gain U.S. manufacturing and distribution rights for an investigational PET imaging agent that could help manage patients with suspected Alzheimer's, should the drug get a green light from the Food and Drug Administration.

The agent, Amyvid, was rejected by the FDA in March over concerns about reader training, but a Lilly spokeswoman told DOTmed News that the company has re-filed with the FDA and expects a response from the agency by the middle of next year.

The companies announced the deal Monday, and Lilly confirmed with DOTmed News that it would involve Amyvid.
DOTmed text ad

New Fully Configured 80-slice CT in 2 weeks with Software Upgrades for Life

For those who need to move fast and expand clinical capabilities -- and would love new equipment -- the uCT 550 Advance offers a new fully configured 80-slice CT in up to 2 weeks with routine maintenance and parts and Software Upgrades for Life™ included.

If approved by the agency, the drug, also called florbetapir F18, would be the first clinical agent approved to measure beta-amyloid plaque deposits linked with Alzheimer's in living patients. It was developed by Avid Radiopharmacueticals, which was bought last year by Lilly.

Lilly said the distribution rights would be non-exclusive. However, the Indianapolis-based company said it would also consider expanding its commercial agreement with PETNET to cover international markets, such as Europe. But for now, the company hasn't disclosed any European plans.

PETNET and Avid had already worked together previously on Amyvid. In April 2010, the companies said PETNET had created doses for clinical trials involving the agent.

Siemens acquired PETNET, the world's biggest PET imaging agent network, when it bought its parent company, CTI Molecular Imaging Inc., in a 2005 deal valued at about $1 billion.

You Must Be Logged In To Post A Comment